Protagenic Therapeutics (Protagenic Therapeutics) Total Current Liabilities : $0.66 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Protagenic Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was $0.66

Protagenic Therapeutics Total Current Liabilities Historical Data

The historical data trend for Protagenic Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Total Current Liabilities Chart

Protagenic Therapeutics Annual Data

Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 1.20 0.66 0.80 1.12 0.66

Protagenic Therapeutics Quarterly Data

Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23

Total Current Liabilities Get a 7-Day Free Trial 1.12 1.25 1.51 1.28 0.66

Protagenic Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Protagenic Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.655 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.66

Protagenic Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.655 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0 + 0

= 0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Protagenic Therapeutics Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Protagenic Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » Total Current Liabilities

Comparable Companies

PCSA THER MYMD ENZN SCPX AZTR XBIO NLSP SNGX CELZ OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX

Traded in Other Exchanges

MBP:Germany

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.protagenic.com

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Executives

Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064

Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421

Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010

Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421

Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010

Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010

Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010

Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017

Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421

Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110

David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165

Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003

Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018

Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367

Protagenic Therapeutics (Protagenic Therapeutics) Headlines

From GuruFocus

Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
By Marketwired Marketwired • 08-17-2021

Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
By Marketwired Marketwired • 06-16-2021

Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
By ACCESSWIRE ACCESSWIRE • 04-26-2022

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
By ACCESSWIRE ACCESSWIRE • 03-22-2023

Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing
By Marketwired Marketwired • 09-08-2020

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering
By Marketwired Marketwired • 04-27-2021

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
By Marketwired Marketwired • 07-06-2021

Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq
By Marketwired Marketwired • 04-29-2021

Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
By Marketwired Marketwired • 08-30-2021

Three High Profile Publications Support the Potential of Protagenic Therapeutics's Synthetic TCAP to Treat Stress-Related Psychological Disorders
By Marketwired Marketwired • 06-11-2018

Protagenic Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Liabilities	Get a 7-Day Free Trial															1.12	1.25	1.51	1.28	0.66

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	0.655	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0	+	0
	=	0.66

Alexander K. Arrow	officer: Chief Financial Officer	PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell	director	3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein	director	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan	officer: COO / Interim President	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen	director, 10 percent owner, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea	director, officer: Chief Executive Officer	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin	officer: Chief Financial Officer	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong	officer: Chief Financial Officer	THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel	officer: Chief Marketing Officer	C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci	director, officer: Exec VP, Corporate Development	C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367